Study on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis

1 1 1

What is this study about?

This clinical trial is focused on studying a type of skin cancer called melanoma that has spread to the brain. Specifically, it involves patients with a genetic change known as the BRAFV600 mutation. The study is testing a combination of three treatments: binimetinib, encorafenib, and pembrolizumab. Binimetinib is taken as a tablet, encorafenib is taken as a capsule, and pembrolizumab is given as an infusion into a vein. The trial aims to see if adding a special type of radiation treatment called stereotactic radiosurgery (SRS) to this combination of medications can help improve outcomes for patients.

Participants in the study will receive either the combination of binimetinib, encorafenib, and pembrolizumab alone or the same combination with the addition of SRS. The study will monitor how the cancer responds to these treatments and how long it takes for the cancer to progress in the brain. The trial will also look at the overall health and quality of life of the participants during the study period. The study is expected to continue until 2030, with participants being closely monitored throughout the trial.

1 initial treatment phase

The treatment begins with the administration of pembrolizumab through an intravenous infusion. This medication is provided as a solution for infusion, specifically KEYTRUDA 25 mg/mL.

Alongside pembrolizumab, two oral medications are taken: binimetinib and encorafenib. Binimetinib is available as Mektovi 15 mg film-coated tablets, and encorafenib is available as Braftovi 75 mg hard capsules.

2 medication schedule

Pembrolizumab is administered every three weeks through an intravenous infusion.

Binimetinib is taken orally twice a day, with or without food.

Encorafenib is taken orally once a day, with or without food.

3 monitoring and assessments

Regular monitoring is conducted to assess the response to treatment. This includes imaging tests such as MRI to evaluate the status of brain metastases.

Health-related quality of life is assessed using specific questionnaires, and cognitive performance is evaluated using the Montreal Cognitive Assessment.

4 follow-up phase

After completing the treatment, follow-up visits are scheduled to monitor the patient’s health and any potential long-term effects of the treatment.

The duration of the follow-up phase is determined based on individual response and overall health status.

Who Can Join the Study?

Provide written informed consent before any trial-specific procedures.
Have at least one measurable lesion in the brain.
All previous cancer treatment side effects (except hair loss and lab values) must be resolved or be mild according to a specific grading system.
Be able to swallow and keep oral medication and not have significant stomach or bowel issues that affect absorption.
Have adequate bone marrow, organ function, and lab test results.
Have adequate heart function.
Women who can have children or men must agree to avoid sexual activity or use effective birth control during the study and for 120 days after treatment. Men must also agree not to donate sperm during this time.
Be affiliated with or a beneficiary of the local social security system or equivalent.
Be willing and able to follow the study protocol, including treatment, visits, exams, and follow-up.
Be at least 18 years old.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, which means being fully active or having some symptoms but being able to carry out light work.
Have Stage IV M1d cutaneous melanoma or unknown primary melanoma that has spread to the brain, confirmed by a tissue test. Patients with mucosal melanomas are not eligible.
Have a specific mutation called BRAFV600E/K/D/R confirmed by a local test.
Be a candidate for SRS therapy, confirmed by a radiation oncologist and neurosurgeon, and documented in the patient file.
Have not received previous combined systemic treatment for melanoma that has spread to distant parts of the body.
Have had no more than one previous local brain treatment for one lesion, such as surgery or SRS.
Be able to undergo a special type of brain scan called gadolinium-enhanced MRI.

Who Cannot Join the Study?

Patients who do not have a BRAF(V600) mutation-positive melanoma. This means the specific type of skin cancer with a certain genetic change.
Patients without brain metastasis. This refers to cancer that has spread to the brain.
Patients who are not within the specified age range for the study.
Patients who are not able to receive the combination therapy of binimetinib, encorafenib, and pembrolizumab. These are specific medications used in the treatment.
Patients who are unable to undergo SRS (Stereotactic Radiosurgery). This is a type of radiation therapy that targets tumors in the brain.
Patients who are considered part of a vulnerable population that the study cannot safely include.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France

Other Sites

Site Name	City	Country
Hopitaux Universitaires Pitie Salpetriere	Paris	France
Hopital Ambroise Pare	Boulogne-Billancourt	France
Hopital Beaujon	Clichy	France
Institut de Cancérologie de l’Ouest	Saint-Herblain	France
Centre Francois Baclesse	Caen	France
Aqprphzfil Pvidjwpz Hwpovfrf Dc Mfrkfwpjx	Marseille	France

Trial status

Country	Status	Recruitment Start
France	Not recruiting	05.09.2022

Trial locations

Investigated drugs:

Binimetinib is a medication used to treat certain types of cancer by blocking specific proteins that promote cancer cell growth. In this trial, it is part of a combination therapy aimed at treating melanoma with brain metastasis.

Encorafenib is another cancer treatment that targets proteins involved in the growth and spread of cancer cells. It is used alongside other medications to enhance the effectiveness of the treatment for melanoma with brain metastasis.

Pembrolizumab is an immunotherapy drug that helps the immune system recognize and attack cancer cells. It is included in the combination therapy to improve the body’s natural defenses against melanoma with brain metastasis.

Stereotactic Radiosurgery (SRS) is a non-invasive radiation therapy that precisely targets brain tumors. In this trial, it is being tested to see if adding it to the combination of binimetinib, encorafenib, and pembrolizumab improves outcomes for patients with melanoma that has spread to the brain.

Melanoma with Brain Metastasis – This is a type of skin cancer that has spread to the brain. It originates from melanocytes, the cells responsible for skin pigmentation. When melanoma cells travel through the bloodstream or lymphatic system, they can form secondary tumors in the brain. The presence of brain metastases can lead to neurological symptoms such as headaches, seizures, or cognitive changes. The progression of the disease involves the growth and spread of these metastatic tumors within the brain. The BRAF(V600) mutation is a specific genetic change that can drive the growth of melanoma cells, making it a target for certain therapies.

Trial ID:

2023-505302-42-00

Protocol code:

UC-0107/1810

NCT ID:

NCT04074096

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?